Volume 3 Supplement 1

Current and Future Applications of Focused Ultrasound 2014. 4th International Symposium: abstracts

Open Access

Patient selection guidelines for magnetic resonance focused ultrasound (MRgFUS) treatment: an updated view

  • Kelli Bryant1 and
  • Suzanne LeBlang1
Journal of Therapeutic Ultrasound20153(Suppl 1):P86

DOI: 10.1186/2050-5736-3-S1-P86

Published: 30 June 2015


The purpose of this retrospective study was to evaluate the selection criteria used to determine patient eligibility for MRgFUS for the treatment of symptomatic uterine fibroids.


373 women with symptomatic uterine fibroids were screened with MRI exams with and without contrast utilizing T2 coronal and axial, T2 fat suppressed sagittal, T1 axial precontrast images, and post contrast fat saturated images in 3 planes. Patients were initially considered clinically eligible if they met the standard published screening criteria/Food and Drug Administration-based treatment guidelines. These selection criteria were expanded on a case-by-case basis if it was felt that a NPV of at least 50% could be obtained or if the patient refused other treatment approaches (myomectomy, hysterectomy, uterine artery embolization).

Results and conclusions

Results: Of the 373 patients (ages 26-61) that underwent pelvic screening, 188 (51%) were considered eligible and 135 (36%) were excluded for the MRgFUS procedure based on the published selection criteria. An additional 50 patients (13%) would have been excluded from treatment based on the published criteria, but were given the opportunity for MRgFUS treatment. Of those 50 patients, 35 patients were treated, with 33 having fibroids >10 cm, 1 having prior liposuction and 1 having multiple small fibroids. Of the 33 patients with fibroids in excess of 10 cm, 11 agreed to have pre treatment with a GnRH agonist while the other 22 patients refused all other interventions besides MRgFUS. 135 patients (36%) were excluded from treatment. The reasons for exclusion are listed in Table 1 below. Using the FDA-based treatment guidelines, 188 fibroids were treated with MRgFUS with an average NPV/fibroid of 66%. Using expanded selection criteria, an additional 60 fibroids were treated with an average NPV/fibroid of 56%.
Table 1

Patients excluded from MRgFUS treatment following MRI screening

Reason for Exclusion

Percentage of Patients (%)

Number of Patients

Fibroid number (>6)



Possible malignancy



Diffuse adenomyosis



Non-enhancing fibroids (calcified, hemmorrhagic, necrotic)



Fibroid size > 10 cm



Fibroid size < 2 cm



Pedunculated fibroid



Hyperintense T2-weighted signal



Metal in beampath



Fibroid location > 12cm from skin



Obesity {subcutaneous fat layer > 4.0 cm)



Prior Liposuction



Conclusions: Using the published selection criteria, 51% of patients who underwent MRI screening were considered candidates for MRgFUS. An additional 13% of patients were brought into the treatment arm of the study after pre-treatment with a GnRH agonist or after considering patient preference. This individualized approach to determining patient eligibility resulted in only a slightly smaller average NPV/fibroid of 56% vs. 66% under the published selection criteria. As physicians acquire more clinical experience with MRgFUS, an expanded selection criterion may allow more women to benefit from this more conservative approach to treating uterine fibroids.


Acknowledgements (Funding)

We would like to thank Lisa Mckenzie and Gina Boykin for their knowledge and dedication in helping to take care of our MRgFUS patients.

Authors’ Affiliations

University MRI


© Bryant and LeBlang; licensee BioMed Central Ltd. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.